APLN and type 1 diabetes mellitus: Thus, it could be hypothesized that the increased plasma apelin observed in type 2 diabetic patients, is, as in type 1 diabetes, a compensatory mechanism devoted to directly decrease insulin resistance since apelin exerts different metabolic actions itself.